A5067964875- HIV Research and Treatment
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Animal Disease Management and Epidemiology
- T-cell and B-cell Immunology
- Vector-Borne Animal Diseases
- Herpesvirus Infections and Treatments
- HIV/AIDS Research and Interventions
- Virology and Viral Diseases
- Cytomegalovirus and herpesvirus research
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- Viral gastroenteritis research and epidemiology
- RNA Interference and Gene Delivery
- Hepatitis B Virus Studies
- Immunodeficiency and Autoimmune Disorders
- Immune responses and vaccinations
- CAR-T cell therapy research
- Immune Response and Inflammation
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- Viral Infectious Diseases and Gene Expression in Insects
National Cancer Institute
2014-2023
National Institutes of Health
2013-2022
Center for Cancer Research
1995-2020
National Cancer Institute
1989-2020
GTx (United States)
2018
Biology of Infection
2017
Institut de Recherche Vaccinale
2005-2011
Cancer Research Center
2010
Weatherford College
2008
University of Pennsylvania
2008
Several isolates of a human type-C retrovirus belonging to one group, known as T-cell leukemia virus (HTLV), have previously been obtained from patients with adult or lymphoma. The tropism HTLV and its prevalence in the Caribbean basin prompted search for it epidemic immune deficiency disorder AIDS. Peripheral blood lymphocytes patient United States two France were cultured growth factor (TCGF) an shown express antigens. Virus U.S. was isolated characterized be related subgroup I. also...
Human T-cell leukemia virus (HTLV) is a human type-C RNA tumor (retrovirus) previously identified in and isolated from several patients with leukemias or lymphomas. The known isolates the United States Japan are closely related found adults an acute malignancy of mature T cells. A retrovirus has been patient (Mo) somewhat different disease (a variant relatively benign hairy cell leukemia). Serum Mo contains antibodies to major internal core protein (p24) HTLV. line established spleen...
We studied the clinical features of 11 patients with adult T-cell lymphoma associated human virus. The were predominantly young, black, and born in southeastern United States. They had an aggressive course, rapid onset disseminated skin lesions or symptoms related to hypercalcemia other metabolic disturbances, both. Common findings included enlargement peripheral, hilar, retroperitoneal lymph nodes, sparing mediastinum; invasion central nervous system, lungs, gastrointestinal tract;...
Human T cell lymphoma leukemia virus (HTLV) is a human retrovirus (RNA tumor virus) that was originally isolated from few patients with leukemias or lymphomas involving mature lymphocytes. Here we report the serum of Japanese adult leukemia, but not tested normal donors, contains high titers antibodies to HTLV. These observations, together data Japan showing endemic in southwest Japan, suggest HTLV involved subtype malignancy, including leukemia.
Antibody prevalences for human T-cell lymphotropic virus (HTLV) types I, II, and III were determined 56 intravenous drug abusers from Queens, NY. While control serum samples lacked antibodies to all HTLV subgroups, seropositivity among users was 41% HTLV-III, 18% HTLV-II, 9% HTLV-I. Infection by HTLV-I -II occurred independently of HTLV-III infection. Blacks had greater antibody prevalence than whites (54% vs 16%) more likely be seropositive or (46% 11%). They exhibited a incidence double...
Immunization with either an Escherichia coli recombinant segment of the human T-cell lymphotropic virus (HTLV-III/LAV) envelope protein (gp120) or deglycosylated gp120 produced antibodies that neutralize HTLV-III/LAV infection in vitro. Virus neutralization titers these antisera were equivalent to those obtained purified native as immunogen. This localizes at least one class neutralizing epitopes carboxyl-terminal half molecule. In addition, prevented HTLV-III/LAV—mediated cell fusion,...
Abstract Extracellular vesicles (EVs), including exosomes and microvesicles, are 30–800 nm that released by most cell types, as biological packages for intercellular communication. Their importance in cancer inflammation makes EVs their cargo promising biomarkers of disease cell-free therapeutic agents. Emerging high-resolution cytometric methods have created a pressing need efficient fluorescent labeling procedures to visualize detect EVs. Suitable labels must be bright enough one EV...
Effector cells armed with Abs can eliminate virus-infected target by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that has been largely overlooked in HIV vaccine development. Here, we show a prime/boost AIDS approach elicits potent ADCC activity correlating protection against SIV rhesus macaques (Macacca mulatta). Priming replicating adenovirus type 5 host range mutant-SIV recombinants, followed boosting gp120, elicited SIV(mac251)-infected cells. In vitro correlated vivo...
This report describes the neurologic manifestations of 36 children with human immunodeficiency virus (HIV) infection. In this cohort, in 16 21 acquired syndrome (AIDS), three 12 AIDS-related complex, and one asymptomatic seropositive children, a progressive encephalopathy developed. Neurologic signs were often detected early but tended to worsen coincident progression immunodeficiency. The presence correlated absence serum neutralizing antibodies HIV poor, usually fatal, outcome. incubation...
A monoclonal antibody specific for the internal p19 protein of a type-C retrovirus (HTLV) isolated from human neoplastic T cells has been developed. Its specificity shown by radioimmune precipitation and affinity chromatography iodinated HTLV proteins. By indirect immune fluorescence this recognizes only HTLV-producing cells. Examination patients with cutaneous cell lymphomas leukemias other types indicated that expression is rare. The will be useful in determining natural reservoir HTLV,...
In this report, we demonstrate the sequence-specific suppression of viral expression in T cells chronically infected with human immunodeficiency virus 1 (HIV-1), using antisense phosphorothioate oligodeoxynucleotides. As a target for intervention, used HIV-1 gene rev, which is essential replication and regulates virion proteins, part, by affecting splicing mRNA. A oligomer complementary to initiation sequence rev had significant selective inhibitory effect on production several proteins...
The human T-cell leukemia/lymphoma virus (HTLV) is a novel Type-C retrovirus isolated from patients with post-thymic malignancies. Thirteen diagnosed in the United States were identified as having antibodies to HTLV and typical clinicopathologic syndrome chracteristic of adult described Japan. most characteristic diagnostic feature our series was presence highly pleomorphic lobated lymphoid cells peripheral blood. Also notable acid phosphatase activity which partially tartrate-resistant...
Human T (thymus-derived)-cell leukemia/lymphoma virus (HTLV) is the first retrovirus consistently isolated from humans. Seroepidemiologic testing for antibodies to HTLV document following. (1) associated with a spectrum of mature T-celllymphoreticular neoplasms. (2) strongly clusters adult T-cell leukemia in Japan and related syndrome, lymphosarcoma Caribbean. (3) Virus-positive infections other areas world share similar clinicopathologic features, some overlap cutaneous lymphoma (CTCL)....
A human type C retrovirus, designated HTLV, previously was isolated from or identified in some patients with leukemias and lymphomas of mature T lymphocytes. HTLV is genetically serologically distinct any known animal retroviruses. The absence proviral sequences DNA normal humans showed that not a ubiquitous endogenous (germ-line transmitted) virus humans. Antibodies to core proteins have been people T-cell neoplasias are particularly prevalent Japanese adult leukemia, suggesting acquired...
ABSTRACT Whereas several recent AIDS vaccine strategies have protected rhesus macaques against a pathogenic simian/human immunodeficiency virus (SHIV) 89.6P challenge, similar approaches provided only modest, transient reductions in viral burden after challenge with virulent, SIV, which is more representative of HIV infection people. We show here that priming replicating adenovirus recombinants encoding SIV env/rev , gag and/or nef genes, followed by boosting gp120 or an polypeptide...